GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

Summary

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.

Timeline

Start

2022-03-11

Primary completion

2027-12-31

Completion

2027-12-31

Drugs

Indications